Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 23433739

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2013 Apr 6
First author
Rummel MJ

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2013 Apr 6;381(9873):1184
    note
    Source null
    related pmid
    Source null
    relationship
    Erratum in
    url
    Source null
  2. citation
    Lancet. 2013 Apr 6;381(9873):1163-5. doi: 10.1016/S0140-6736(12)61965-5.
    note
    Source null
    related pmid
    23433738
    relationship
    Comment in
  3. citation
    Nat Rev Clin Oncol. 2013 May;10(5):251-2. doi: 10.1038/nrclinonc.2013.53.
    note
    Source null
    related pmid
    23591322
    relationship
    Comment in
  4. citation
    Lancet. 2013 Sep 28;382(9898):1093-4. doi: 10.1016/S0140-6736(13)62016-4.
    note
    Source null
    related pmid
    24075043
    relationship
    Comment in
  5. citation
    Lancet. 2013 Sep 28;382(9898):1094-5. doi: 10.1016/S0140-6736(13)62018-8.
    note
    Source null
    related pmid
    24075044
    relationship
    Comment in
  6. citation
    Lancet. 2013 Sep 28;382(9898):1094. doi: 10.1016/S0140-6736(13)62017-6.
    note
    Source null
    related pmid
    24075045
    relationship
    Comment in

Authors and identifiers

  1. name
    Rummel MJ
    type
    Author
  2. name
    Niederle N
    type
    Author
  3. name
    Maschmeyer G
    type
    Author
  4. name
    Banat GA
    type
    Author
  5. name
    von Grünhagen U
    type
    Author
  6. name
    Losem C
    type
    Author
  7. name
    Kofahl-Krause D
    type
    Author
  8. name
    Heil G
    type
    Author
  9. name
    Welslau M
    type
    Author
  10. name
    Balser C
    type
    Author
  11. name
    Kaiser U
    type
    Author
  12. name
    Weidmann E
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Rummel MJ
    type
    Author
  2. name
    Niederle N
    type
    Author
  3. name
    Maschmeyer G
    type
    Author
  4. name
    Banat GA
    type
    Author
  5. name
    von Grünhagen U
    type
    Author
  6. name
    Losem C
    type
    Author
  7. name
    Kofahl-Krause D
    type
    Author
  8. name
    Heil G
    type
    Author
  9. name
    Welslau M
    type
    Author
  10. name
    Balser C
    type
    Author
  11. name
    Kaiser U
    type
    Author
  12. name
    Weidmann E
    type
    Author
bibliography ids
  1. nci-bib-d1191721ccd0064d506b4494
book metadata
content sha256
f4ad35172ca734ac076fcb789fd3c9ac63d367e9524b292683149e46f1958aac
document type
citation
dois
  1. 10.1016/S0140-6736(12)61763-2
electronic publication date
display
2013 Feb 20
precision
day
year
2013
evidence scope
bibliographic_metadata_only
id
pubmed:23433739
immutable id
pubmed:23433739@f4ad35172ca734ac076fcb789fd3c9ac63d367e9524b292683149e46f1958aac
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
9873
name
Lancet (London, England)
nlm unique id
2985213R
pages
1203-10
volume
381
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2013 Apr 6;381(9873):1184
    note
    Source null
    related pmid
    Source null
    relationship
    Erratum in
    url
    Source null
  2. citation
    Lancet. 2013 Apr 6;381(9873):1163-5. doi: 10.1016/S0140-6736(12)61965-5.
    note
    Source null
    related pmid
    23433738
    relationship
    Comment in
  3. citation
    Nat Rev Clin Oncol. 2013 May;10(5):251-2. doi: 10.1038/nrclinonc.2013.53.
    note
    Source null
    related pmid
    23591322
    relationship
    Comment in
  4. citation
    Lancet. 2013 Sep 28;382(9898):1093-4. doi: 10.1016/S0140-6736(13)62016-4.
    note
    Source null
    related pmid
    24075043
    relationship
    Comment in
  5. citation
    Lancet. 2013 Sep 28;382(9898):1094-5. doi: 10.1016/S0140-6736(13)62018-8.
    note
    Source null
    related pmid
    24075044
    relationship
    Comment in
  6. citation
    Lancet. 2013 Sep 28;382(9898):1094. doi: 10.1016/S0140-6736(13)62017-6.
    note
    Source null
    related pmid
    24075045
    relationship
    Comment in
outcomes validated
false
pmid
23433739
provenance
batch id
99e008dabc339d38fd44
provider
NCBI PubMed ESummary
record sha256
6ed01cf608251a468538b9d0f02abedf35046260b434f759d2e6f72d1802ba9e
response sha256
804916232567480946eda9a00aff276bc44fd9a6d15d9336e773a9c803123d39
retrieved at
2026-09-09T23:46:55.094762+00:00
publication date
display
2013 Apr 6
precision
day
year
2013
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/23433739/
title
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

Preserved source evidence · Independent clinical review pending · Not medical advice